3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD 4.080
-0.160 (-3.77%)
At close: Feb 13, 2026
3D Medicines Revenue
3D Medicines had revenue of 209.17M CNY in the half year ending June 30, 2025, a decrease of -40.67%. This brings the company's revenue in the last twelve months to 448.39M, down -8.27% year-over-year. In the year 2024, 3D Medicines had annual revenue of 445.65M, down -29.81%.
Revenue (ttm)
448.39M CNY
Revenue Growth
-8.27%
P/S Ratio
2.04
Revenue / Employee
2.45M CNY
Employees
183
Market Cap
1.00B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.65M | -189.30M | -29.81% |
| Dec 31, 2023 | 634.95M | 67.56M | 11.91% |
| Dec 31, 2022 | 567.39M | 507.13M | 841.57% |
| Dec 31, 2021 | 60.26M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 589.59M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Brii Biosciences | 31.53M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |